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Abstract 
Green Toxicology refers to the application of predictive toxicology in the sustainable development and production of 
new less harmful materials and chemicals, subsequently reducing waste and exposure. Built upon the foundation of 
“Green Chemistry” and “Green Engineering”, “Green Toxicology” aims to shape future manufacturing processes and safe 
synthesis of chemicals in terms of environmental and human health impacts. Being an integral part of Green Chem‑
istry, the principles of Green Toxicology amplify the role of health‑related aspects for the benefit of consumers and 
the environment, in addition to being economical for manufacturing companies. Due to the costly development and 
preparation of new materials and chemicals for market entry, it is no longer practical to ignore the safety and environ‑
mental status of new products during product development stages. However, this is only possible if toxicologists and 
chemists work together early on in the development of materials and chemicals to utilize safe design strategies and 
innovative in vitro and in silico tools. This paper discusses some of the most relevant aspects, advances and limitations 
of the emergence of Green Toxicology from the perspective of different industry and research groups. The integration 
of new testing methods and strategies in product development, testing and regulation stages are presented with 
examples of the application of in silico, omics and in vitro methods. Other tools for Green Toxicology, including the 
reduction of animal testing, alternative test methods, and read‑across approaches are also discussed.
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Background
Over the past two decades, the movement of Green 
Chemistry has become a new standard embraced for the 
development of less harmful materials and chemicals 
that are safer for both the environment and consumers 
[1, 2]. The twelve principles of Green Chemistry outlined 
by Anastas and Warner [3] and mnemonically presented 
by Tang et  al. [4] (PRODUCTIVELY; prevent wastes; 
Renewable materials; omit derivatization steps; degra-
dable chemical PRODUCTS; use safe synthetic methods; 
catalytic reagents; temperature, pressure ambient; in-
process monitoring; very few auxiliary substances; E-fac-
tor, maximized feed in products; low toxicity of chemical 
products; yes, it’s safe) are a guideline to develop less-
hazardous products through safer methods that mini-
mize harmful waste and exposure (i.e. benign-by-design). 
Many of these goals, along with the principles of Green 
Engineering [4], strive for sustainability with chemi-
cal synthesis and molecular design [2] and are adopted 
by major industries (e.g. pharmaceutical and chemical). 
However, currently and for the future, the inclusion of 
aspects related to consumer and environmental health 
has become more and more important. Thus, considera-
tions about the possible toxic activity of a certain mol-
ecule or material during its development for the market 
are crucial not only for the economic success but also for 
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its consumer acceptance. Taking this aspect into account, 
Green Toxicology will strengthen the marketing process 
and avoid serious setbacks.
Green Chemistry practices have been adopted into 
mainstream research and manufacturing since the early 
1990s. Success stories of the application and study of 
Green Chemistry include the use of microbes as environ-
mentally benign synthetic catalysts [5–7] as well as the 
development of fully biodegradable bags with the use of 
compostable polyester film (e.g.  Ecoflex®; [8–10]). The 
efforts of Green Chemistry have resulted in the reduc-
tion of hazardous waste in a cost-effective manner that 
has maintained the need, efficacy and safety of products 
for consumers. For example, the development of water-
based acrylic alkyd paints with low volatile organic 
carbons (VOCs) from recycled soda bottle plastic (poly-
ethylene terephthalate; PET), acrylics and soybean oil 
reduced approximately 350,000 kg of VOCs during man-
ufacturing in 2010 [11]. Thus, Green Chemistry practices 
are now incorporated into higher education, prominent 
at scientific conferences and in journals, and are easily 
recognized by the industry for their advantageous ben-
efits commercially, environmentally and publicly [12, 13]. 
However, toxicity, which is a large part of risk and haz-
ard assessments, is not intrinsically considered in the 
Green Chemistry and Green Engineering approaches. 
For example, the use of solvents, which consistently 
account for approximately 80–90% of the materials used 
in a typical pharmaceutical batch chemical operation 
[14], may play a dominant role in the overall toxicity of 
any given manufacturing process, resulting in excess and 
potentially hazardous waste. Due to the sometimes irre-
placeable utility of solvents, it is vital that the toxicologi-
cal hazards of all aspects (health, safety, and lifecycle) of 
solvent selection, use, interaction, processes and disposal 
be evaluated.
A complementary tool for Green Chemistry and Green 
Engineering that incorporates the toxicological risk and 
hazard assessment of the design to disposal of products 
and materials is the concept of Green Toxicology. Green 
Toxicology [15] describes the application of predictive 
toxicology in the design, manufacturing, use and disposal 
of new materials and chemicals. The objective of such an 
application is to contribute to products, which are safer 
for humans and the environment by using intelligent and 
predictive testing strategies of toxicology. Maertens et al. 
[1] outlines several considerations, which might form the 
basis of future principles of Green Toxicology, the basis of 
which are: (1) benign-by-design (also known as safety-by-
design); (2) test early—produce safe; (3) avoid exposure 
and thus testing needs; and (4) make testing sustainable. 
These considerations of Green Toxicology are outlined in 
Fig. 1, which encompass the fundamental ideas of Green 
Chemistry, but which additionally utilize predictive toxi-
cological testing tools and strategies. In other words, 
Green Toxicology aims to expand the respective princi-
ples of Green Chemistry to develop and produce prod-
ucts that are less toxic, with safer processes that result in 
less waste and exposure, utilizing toxicological tools and 
strategies. While there are many overlapping features 
Safety-by-design
Test early, produce safe
Support the Development of and use predicve Test 
Methods
Avoid Exposure and thus Tesng Needs
Make Tesng sustainable
Transdisciplinary Educaon in Toxicology
Encourage the Public and Stakeholder to support the Idea 
of Green Chemistry and Green Toxicology
C
onsulting by Experts
Fig. 1 Principles of Green Toxicology
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and principles among the Green Chemistry, Engineering 
and Toxicology, the key difference of Green Toxicology is 
that it promotes the incorporation of toxicological con-
siderations throughout the discovery, development, and 
production of new materials and chemicals, which are 
discussed in this paper.
Toxicity testing is a prerequisite for reducing the risks 
to humans and the environment. However, sustain-
able practices, which are the pillars of Green practices, 
require the reduction in not only animal testing but of 
the chemicals used during toxicity testing. Green Toxi-
cology practices promote and encourage the use of new 
and innovative techniques and strategies that reduce 
the use of animals for testing, the amounts of chemi-
cals used and disposed of during tests; and increase the 
consideration of toxicity in the synthesis, use and regu-
lation of chemicals. Frontloading of toxicity assessments 
(i.e. not waiting until regulatory or market release until 
safety assessments have to be done) by means of intelli-
gent and predictive testing strategies are key to the Green 
Toxicology approach. This implies that, often, many more 
substances still under consideration have to be assessed, 
and that quantities of substances and resources for test-
ing are limited. These limitations call for the use of com-
putational and higher-throughput in  vitro approaches. 
In such a way, Green Toxicology becomes an integrated 
component of the Green Chemistry approach in that 
an understanding of the adverse outcomes and associ-
ated toxicity of chemical development, use, and disposal 
are recommended. Toxicological tools, such as in silico, 
omics and in  vitro methods allow for a better under-
standing of the mechanisms of toxicity, identification 
of common structural activity relationships (SAR) and 
associated effects, and thus, can often eliminate potential 
chemical candidates early on based on predicted toxicity 
(e.g. “failing early and failing cheaply”).
Green Toxicology offers many advantages in the prac-
tices and application of Green Chemistry, which are dis-
cussed in this paper. The Green Toxicology principles 
outlined by Maertens et al. [1] and Fig. 1 provide a frame-
work for designing chemicals that are safer for humans 
and the environment by utilizing new and innovative 
predictive toxicological tools and strategies. This paper 
discusses some of the aspects of Green Toxicology with 
respect to improving the integration of Green Toxicol-
ogy with Green Chemistry practices to produce safer, 
less harmful products. The integration of new testing 
methods and strategies in product development, test-
ing and regulation stages are presented with examples of 
the applications of in vitro, omic, and in silico methods. 
Other tools for Green Toxicology, including the reduc-
tion of animal testing, alternative test methods, and read-
across approaches are also discussed. Examples of lessons 
that can be learned from past activities are also discussed 
with respect to reducing current and future risks (e.g. 
late lessons from early warning; precautionary principle; 
[16–18]). This paper also examines some of the stages of 
product development, regulation, use and disposal that 
can or have benefited from the incorporation of Green 
Toxicology practices. In addition, some of the most rel-
evant aspects, advances and limitations of the emergence 
of Green Toxicology from the perspective of different 
industry and research groups will be discussed.
Integration of Green Toxicology in discovery, 
development and production practices
In order to efficiently develop new compounds or prod-
ucts with the desired technological or biological traits 
and lesser toxicity, many different structures need to be 
evaluated. Synthesizing these new molecules, often with 
complex chemical structures, in sufficient amounts is 
very demanding. The discovery and development of new 
products and active ingredients (AIs) thus rely on reac-
tion screening and route scouting with high-throughput 
experimentation incorporating automated solid and liq-
uid handling for rapid and routine screening (e.g. evalu-
ate typically 100 reactions simultaneously at 1 mL scale) 
[19]. Principle design is incorporated in all aspects of the 
AI process, including reaction screening, optimization, 
critical parameter identification and process response 
surface modelling [19]; however, the toxicity of all steps 
of chemical development and processing (e.g. intermedi-
ates, solvents, catalysts, etc.) must be considered.
Identifying the anticipated biological traits of AIs 
and products often requires only one assay, as the tar-
get is known. In contrast, the “off-target” specification 
(reduced toxicity) requires many tests, including those 
with animals. The reduction of animal testing is another 
pillar of ethical-based sustainability. Animal testing ena-
bles the assessment of toxic effects and thus helps to 
develop less toxic compounds. Animal testing is actually 
performed rather late during the development of new 
chemicals. However, even a very limited safety testing 
programme, according to the Organisation for Economic 
Co-operation and Development (OECD) guidelines, 
would require up to 0.5  kg of the compound. There are 
a number of other negative aspects associated with ani-
mal testing including animal welfare and ethics, as well as 
the heavy reliance and use of time (months to years per 
assay), money (thousands to millions of dollars per test-
ing programme) and resources [15, 20]. In addition, the 
uncertainty associated with the extrapolation from ani-
mals to humans may be accounted for using uncertainty 
or safety factors; however, many variables such as body 
weight, homology of genetic material and enzymes, as 
well as anatomy and physiology of organisms and humans 
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must be considered to make confident conclusions about 
human hazard assessments from animal data [15, 21].
Animal testing will, for the foreseeable future, be an 
essential and compulsory step in assessing the risk and 
regulation of chemical development, as various industrial 
sectors have different legal constraints placed upon them 
as consequences of registration and approval procedures 
worldwide. However, new tools and Green Toxicology 
strategies to relate mechanistic information obtained 
through in silico, toxicogenomic and in vitro approaches 
for animal and human effects have been investigated as 
alternative or complementary tools for in vivo tests. For 
example, with the development of alternative in  vitro 
methods, test substance demand is generally reduced to 
less than 500 mg per assay. Hence, with only a few grams 
of a new compound, many tests can be performed. The 
use of predictive toxicological tools and strategies in 
Green Toxicology practices are discussed below.
Predictive toxicology using in silico tools
In silico toxicology relies on the use of computational 
methods to analyse, model, and predict the toxicity of 
chemicals, which complement traditional and innovative 
toxicity tests for risk and hazard assessments. The use of 
in silico tools not only improve predictive toxicology, but 
also contributes towards the prioritization of chemicals, 
provides insight into future toxicity tests, and minimizes 
late-stage failures in chemical design (i.e. test early, pro-
duce safe). These advantages all aid in the incorporation 
of Green Toxicology in the development of new chemi-
cals and products that benefit both the environment and 
consumers. In silico tools like the United States Environ-
mental Protection Agency’s (U.S. EPA’s) ToxCast™ [22], 
part of the Toxicology in the twenty first century (Tox21), 
is a publicly available high-throughput toxicity dataset of 
thousands of chemicals that should be better utilized for 
data mining to advance Green Toxicology efforts in prod-
uct development. Pertinent data from such in silico tools 
can provide crucial insight early on in the design process 
based on access to hundreds of measured and modelled 
assays used to screen chemicals, concentration–response 
curves, animal toxicity studies, and endocrine disrupting 
screening programmes that can advance Green Toxicol-
ogy efforts [22, 23].
Similar success for Green Toxicology efforts can arise 
from the use of (quantitative) structural activity rela-
tionships [(Q)SARs], the use and applicability of which 
may lead to more successful Predictive Toxicology. 
QSARs are a predictive tool that provide insight into 
the potential toxicity of chemicals based on patterns of 
structure–function relationships from similar chemicals 
whose activities have already been assessed. Successful 
use of QSARs requires a sufficient amount of input data 
in order to support structure–toxicity relationships for 
risk assessment. A number of computerized models have 
been developed and improved to accommodate large 
datasets from high-throughput screening efforts (i.e. 
ECOSAR; Toxicity Estimation Software Tool; TEST; [24, 
25]). As outlined by Anastas [15], QSAR approaches have 
been successfully used for the risk assessments of a num-
ber of chemicals including dioxins and furans, polychlo-
rinated biphenyls (PCBs) and polyaromatic hydrocarbons 
(PAHs). However, there are a number of limitations of 
rule-based SAR and the correlative QSAR approaches 
[26]. Both are limited by the availability and quality of 
input data (“trash in, trash out”). Empiric rules are often 
derived from rather few compounds and not evaluated 
against large sets of chemicals. In addition, correlative 
approaches based on multiple chemical descriptors often 
suffer from over-fitting of parameters, especially when 
the number of parameters and chemicals of the train-
ing set are not proportionate. It is important to note that 
up until now no such approach has been internationally 
validated with chemical sets, which were not part of the 
training set (external validation), and broadly accepted.
Additional challenges for the use of in silico meth-
ods are that toxicological studies, to a large extent, are 
done by the industrial sector, and thus are used for reg-
istration as proprietary data and are not typically pub-
lished or publicly available. This is especially true for the 
high-quality, standardized test data produced accord-
ing to international test guidelines under quality assur-
ance schemes such as Good Laboratory Practice (GLP). 
There was a pivotal change in the sharing and availabil-
ity of such data, when for the first time, the European 
REACH legislation mandated that dossier summaries be 
published, making data readily available on a new scale. 
While this, together with the enormous testing demands 
of REACH [27, 28], stimulates the development of in sil-
ico approaches, the actual availability via the website of 
the European Chemical Agency (ECHA) is cumbersome 
and not machine readable. At the same time, REACH has 
made study data a commodity as owners have to be reim-
bursed by other registrants, which has lowered the will-
ingness to freely share data. In addition, an approach that 
aggregates the use of data for in silico approaches, which 
does not require legitimate access to study dossiers, is 
lacking. However, making these data available for the 
OECD (Q)SAR Toolbox [29] and the European Chemi-
cal Industry Council’s (CEFIC) AMBIT tool [30] signals 
a step towards data interpretation by ECHA. In order to 
make these most valuable data more broadly available, 
the information was downloaded in its entirety, organ-
ized in a database and made machine readable by natural 
language processing [31]. This new database, paralleled 
by the creation and release of various other smaller 
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databases with legacy data, which will be combined in 
the future, enables the analysis of the chemical landscape, 
the assessment of performance of traditional tests, and 
the development of new tools [32]. Early examples dem-
onstrate such uses for oral acute toxicity [33], eye irrita-
tion [34] and skin sensitization [35].
Furthermore, the grouping of substances and read-
across approaches were developed for filling data gaps 
in registrations of chemicals. Read-across approaches 
utilize weight-of-evidence approaches to make use of 
shared properties of an untested compound to a known 
compound. While sharing many characteristics of a 
QSAR, read-across approaches do not seek a mathemati-
cal formula for larger parts of the chemical universe but 
instead are based on “local” similarity and shared proper-
ties of chemicals [36, 37]. In addition to the similarity in 
the structure and physicochemical properties, biological 
data are also used to compare biological similarity among 
chemicals in read-across approaches. Good Read-Across 
Practices (GRAPs) were created and developed by the 
European Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH) legislation as a result 
of the broad use of read-across approaches and the need 
to establish standards [36, 38]. The GRAP collaboration 
formed to further this approach and addresses aspects 
such as regulatory acceptability, the use of biological 
support data [37], and the applicability to nanomateri-
als or complex mixtures. The major advantage is that 
such an approach can actually be formally validated and 
uncertainties with any prediction can be quantified. The 
emergence of professional tools and services promises a 
much broader use of computational approaches both for 
REACH registration and other similar legislations world-
wide, as well as for Green Toxicology practices.
Predictive toxicology using omics and in vitro tools
In the initial stages of chemical development, the identi-
fication of the sequential processes and perturbations of 
biological pathways at a molecular level (e.g. molecular 
initiating events; MIE) through to the cellular or organ 
level leading to an adverse outcome provides insight into 
the SAR and can allow for the grouping of similar mecha-
nisms of biological response [39]. These are the princi-
ples of adverse outcome pathways (AOPs), which can 
bridge the gap between responses on the cellular level to 
that of the whole organism, population, community and 
possibly ecosystem [39–42]. The use of toxicogenomic 
data and molecular techniques (i.e. omics; transcrip-
tomics, proteomics and metabolomics) provides insight 
into mechanisms of action, and although not explicitly 
considered in regulatory decision making, omics data 
provide toxicological weight-of-evidence for the dis-
covery and development of safe chemicals. Ankley et al. 
[42] outline a framework for AOPs, in which uncertain-
ties and priorities associated with the toxicity of chemi-
cals can be identified through either causal, mechanistic, 
inferential, or correlation based relationships; all derived 
from in  vitro (including omics techniques), in  vivo, or 
computational tests (e.g. QSARs, ToxCast, etc.). AOPs 
can help to improve across-chemical extrapolation and 
predictions of toxicity for chemicals that trigger the same 
MIE, which can be used to help design safer chemicals 
and products [15]. In addition, the adverse outcomes of 
in  vitro tests can be compared with different levels of 
biological organization that are of regulatory relevance, 
which may reduce the need or reliance of live animal 
testing. However, the current level of detail of AOPs are 
mostly narrative and not quantitative, thus there is a 
need to move to more molecularly defined mechanisms, 
for which the term pathway of toxicity (PoT) has been 
coined [43], in order to allow for modelling. With PoTs, 
mechanism-based read-across studies will be feasible if 
all receptors within a potential pathway are examined in 
biological testing.
AOPs and PoTs will have major implications for the 
advancement of predictive toxicology, an important tool 
which would improve Green Toxicology approaches in 
developing and designing safer chemicals. An under-
standing of the molecular structure, functionality and 
adverse outcomes associated with chemicals is essential 
in aiding in the benign-by-design concept. In vitro assays 
are typically rapid, with high-throughput and large data 
output that can be reliably reproducible and cost effec-
tive. These qualities are particularly important for the 
safety and hazard assessment of new products, which 
can result in substantial costs for failures and problems 
detected late in the development and regulatory testing 
phase. In addition, many in vitro methods produce mech-
anism-specific data, which is another important aspect 
that can aid with the design of alternative compounds 
with lesser toxicity. With newer and more innovative 
in  vitro tests, the focus moves more towards chronic 
exposures at low concentrations on cells and organ sys-
tems rather than the traditional adverse effects observed 
in in  vivo animal tests that are often conducted at high 
doses. Furthermore, the results of in  vitro testing (e.g. 
 IC50 values in enzyme or receptor assays) could be used 
to develop predictive in silico tools. With the availability 
of such computational methods, chemists can test and 
screen their new structures for warnings, and learn to 
avoid the synthesis of toxic compounds at earlier stages 
of development. As such, the development of in  vitro 
methods complement and may eventually reduce the 
essential use of in  vivo studies, which directly supports 
the principles of Green Toxicology. Thus, with the addi-
tion of any new in vitro method for (eco)toxicity testing 
Page 6 of 16Crawford et al. Environ Sci Eur  (2017) 29:16 
we will get one step closer towards an integrated process 
of gaining early toxicological information and adapting 
substance synthesis, leading to the efficient development 
of green chemicals and products with reduce toxicity.
The new approaches and scientific advances in molecu-
lar, cellular and computational toxicology can lead to a 
better application of predictive toxicology in the manu-
facturing of new materials and chemicals, which directly 
supports Green Toxicology. Predictive toxicology aims 
to develop new and innovative non-animal tests that do 
not simply duplicate existing animal tests but also pro-
vide a new scientific basis for product development and 
safety testing. Hence, the objective of such an application 
is to complement and extend traditional toxicity testing 
through a better understanding of toxicity pathways that 
contribute to products that are safer for humans and the 
environment. The incorporation and consideration of 
toxic potential and outcomes early in the design phase is 
an essential component of Green Toxicology and requires 
collaboration among chemists, toxicologists, industry, 
and regulators. Alternatives to current mandatory testing 
protocols are likely to influence future regulatory policy 
in Europe. However, if these new tools and methods for 
product development and risk assessment are to become 
widely accepted, then policy makers and regulators need 
to be informed and persuaded of the benefits of these 
alternative approaches and applications.
Precautionary principle
Additional lessons for Green Toxicology can be learned 
from past product development and production through 
the application of the precautionary principle [17, 18]. 
The precautionary principle is applied in situations when 
harm to either the environment or human life does not 
need to be conclusively proven in order for risk to be 
addressed through discretionary decisions and policies. 
In some instances, the precautionary principle, often 
observed, is not distinguished from a “right”, which is 
respected and is a statutory requirement in some Euro-
pean Union member states [44]. In this respect, Green 
Toxicology can incorporate the precautionary principle 
by limiting the suspect or potential adverse toxicologi-
cal consequences during the discovery, development and 
production of safer and more sustainable products. As 
such, knowledge about the previous selection of occu-
pational, public health and environmental hazards can 
be examined to determine if further or earlier measures 
could have been employed to prevent harm (e.g. methyl 
tert-butyl ether replacement of lead in petrol; [16]). This 
concept is known as “late lessons from early warnings” 
and is often associated with the precautionary principle. 
Although often neglected, the precautionary principle 
offers many lessons and improvements that can be of use 
to developing products that are less harmful and should 
be a main driving force behind not only Green Toxicol-
ogy but also Green Chemistry.
Green Toxicology and animal testing: a chemical 
company’s perspective
Traditionally, the development of alternative testing 
methods in Europe was largely driven by ethical ration-
ales such that studies were targeted for their use of many 
animals, or for their high potential to result in pain and 
suffering (e.g. skin and eye irritation testing). Regula-
tory rationales were also an additional driver of alter-
native test methods, particularly those that identified 
compounds with alerts for “cut-off” hazards, such as 
mutagenicity and endocrine disruption. Therefore, the 
currently validated in  vitro assays particularly apply to 
the aforementioned endpoints [45, 46].
In the following paragraphs, a brief overview is pro-
vided concerning the 3Rs method currently employed at 
BASF, which are used within a screening context to avoid 
the development of compounds with an unfavourable 
hazard profile (i.e. concept of Green Toxicology).
Skin and eye irritation studies
The traditional in vivo Draize irritation test for skin and 
eyes, in which a restrained, conscious animal is exposed 
(dermal and ocular, respectively) to a test substance for a 
set amount of time to determine toxicological effects, has 
long since been criticized for the limitations in species 
differences, subjective scoring, and experimental vari-
ability. The replacement of the Draize test for skin irrita-
tion was historically one of the first steps towards the full 
replacement of animal testing. BASF, and similar chemi-
cal companies, use two methods suitable to provide data 
for classification as corrosive (Epiderm™ skin corrosion 
test) or irritant (Epiderm™ skin irritation test) to the skin. 
These tests are employed within the context of a simple 
testing strategy described elsewhere [47–50]. In brief, 
a test substance is applied topically to a reconstructed 
human epidermis (RhE) that closely mimics the biochem-
ical and physiological properties of the upper parts of 
the human skin using human derived non-transformed 
keratinocytes as cell sources. The indication of corrosive 
and irritant test substances is determined by their abil-
ity to decease cell viability (cytotoxicity) below defined 
threshold levels as measured via the MTT-assay.
For eye irritation, the situation is essentially quite 
similar. The replacement of the Draize test for eye irri-
tation again was achieved by two methods. The ex  vivo 
Bovine Corneal Opacity and Permeability (BCOP; [51, 
52]) eye irritation test is used to identify strong eye irri-
tation potential and the in  vitro EpiOcular™ eye irrita-
tion test (EIT) is used to evaluate the irritation potential 
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of compounds to the eye. The BCOP and similar ex vivo 
tests utilize slaughterhouse material to assess the severe 
eye irritation potential of a test substance through its 
ability to induce opacity and increased permeability in, 
for example, an isolated bovine cornea. In contrast, the 
EIT and similar tests use the commercially available 
reconstructed human cornea-like epithelium (RhCE), 
which closely mimics the histological, morphological, 
biochemical and physiological properties of the human 
corneal epithelium to determine if a test substance is an 
eye irritant based on its ability to induce cytotoxicity in 
RhCE tissue, as measured by the MTT assay. These tests, 
and alternatives, are again used within the context of 
a simple testing strategy and described in further detail 
elsewhere [52–56].
Skin sensitization studies
Skin sensitization is a process more complex than skin 
or eye irritation, and includes several key events such as 
(1) dermal penetration, (2) protein reactivity, (3) induc-
ing stress responses in keratinocytes, (4) activation of 
immune cells (dendritic cells) in the skin, and (5) their 
translocation to the lymph nodes. Given this complex-
ity, it is difficult to imagine one single test that would be 
able to incorporate all of these steps [57]. Therefore, the 
development of an in vitro testing approach for skin sen-
sitization resulted in the best solution [58], consisting of 
three assays addressing hazard identification according 
to the abovementioned key events 2–4. Protein reactiv-
ity is measured in the Direct Peptide Reactivity assay 
(DPRA) [59], stress responses are measured in Keratino-
cytes in either KeratinoSens [60, 61] or LuSens assays 
[62, 63], and immune cell activation is measured in the 
Human Cell Line Activation Test (h-CLAT) [64]. Empiri-
cal evidence for more than 200 compounds has shown 
that the best match with known human skin sensitizers 
is obtained by a “majority rule”, such that if two or more 
assays are positive, the compound is a skin sensitizer, 
while if two or more are negative, it is not [65]. With this 
testing strategy, a correlation with human skin sensitizers 
is obtained, which is slightly better than that obtained in 
the local lymph node assay (LLNA) [66, 67].
Acute toxicity testing
The endpoint of systemic toxicity has not been of major 
interest to chemical companies and regulatory bodies. 
With good intention, it was proposed to use the results 
of cytotoxicity testing to determine the starting dose for 
acute oral toxicity testing. However, it should be noted 
here that good intention is not always a good guidance. 
With years of experience following this principle, a 
post validation study demonstrated that dose selection 
based on expert knowledge provided better results than 
following the cytotoxicity guidance, which was not sig-
nificantly better than a fixed starting dose of 300 mg/kg 
b.w. [68]. Such expert knowledge was determined from 
information about the substance class or comparable 
formulation. Thus, Green Toxicology, which utilizes and 
considers all available information about a test substance 
through, for example, (Q)SAR, read-across and group-
ing of substances approaches may lead to reductions in 
the amount of chemicals and animals required for testing 
and development of new substances.
Endocrine disruption
To screen for compounds with endocrine effects, two 
in  vitro systems are often used that address the most 
common causes for endocrine activity: (1) agonist or 
antagonist effects on the androgen receptor (AR) or 
estrogen receptor (ER) and (2) interference with ster-
oid synthesis. There are a variety of in vitro, wildlife and 
mammalian screen tests available to screen for endo-
crine disruptor activity, with details on each provided 
elsewhere [69]. In particular, the in vitro Yeast Estrogen 
Screen (YES)/Yeast Androgen Screen (YAS) assays are 
often used to screen for analyse effects on the AR and 
ER. The YES and YAS assays consist of yeast cell lines in 
which the human AR and ER have been introduced and 
coupled with a reporter gene that produces an enzyme. 
Activation and deactivation of either receptor are mon-
itored by the change in colour of a dye sensitive to the 
activity of the enzyme. If deemed necessary, a follow-up 
is carried out at later stages of testing for endocrine activ-
ity with a refined 14- or 28-day study in which a blood 
metabolome analysis is included. Additional testing strat-
egies for endocrine testing have been reported elsewhere 
[70, 71].
Neurotoxicity
Another important aspect of systemic toxicity, with 
respect to avoidance of chemicals, with a problematic 
hazard profile is neurotoxicity. For screening purposes, 
the “neurons on a chip” assay is utilized [72, 73]. In this 
assay, primary neurons are grown on chips connected 
with a device that measures the spontaneous firing of the 
neurons. Compounds that stimulate or attenuate neu-
ronal activity can be monitored by the changes in the fir-
ing rates of the neurons [74, 75].
Developmental toxicity
The last, and possibly the most important endpoint in 
toxicology, which has been investigated in screening 
strategies, is the toxic effects on development. It should 
be noted here that relatively little is unfortunately known 
about the modes of action involved in developmental 
toxicity, in comparison with many endpoints in systemic 
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toxicity such as neurotoxicity, endocrine effects or car-
cinogenicity. Therefore, mode of action-based screens 
are not readily available. Two more holistic approaches 
are used to assess developmental toxicity: (1) the chick 
embryotoxicity screening test (CHEST) [76] and (2) the 
fish embryo toxicity (FET) test [77, 78]. In both assays, 
the development of a complete embryo is monitored and 
evaluated during certain embryonic and foetal stages. As 
such, these tests are very close to being animal studies 
but are not considered as such because of the very early 
timing of testing and the absence of a maternal organism 
being exposed. A third test for assessing developmental 
toxicity is the mouse embryonic stem cell test (EST; [79–
81]). In this test, the differentiation of pluripotent stem 
cells into cardiomyocytes are evaluated, and the interfer-
ence with the normal differentiation process is a measure 
for the compound’s developmental toxicity potential [80]. 
It should be noted that all of the abovementioned tests 
are associated with certain limitations, such as over-sen-
sitivity for acutely toxic compounds, over-sensitivity for 
compounds that are irritating/corrosive, lack of metabo-
lism, water solubility, etc. Nevertheless, with the inclu-
sion of additional endpoints, such as placental transfer 
(which can be measured in vitro), reasonable prediction 
values can be obtained for certain classes of chemicals 
[82]. However, it is clear that a better understanding of 
AOPs in developmental toxicity will be necessary to 
develop a series of targeted in vitro assays to entail better 
screening for this very important endpoint.
New tools
With new omics technologies becoming more readily 
available, we are now at a point where there is a chance 
to tackle complex toxicological concerns, such as sys-
temic toxicity. Following the successful development of 
a metabolomics based approach to predict systemic tox-
icity from a single drop of blood from short-term toxic-
ity studies [83], the potential of this technology using an 
in vitro approach is being explored. A proof of principle 
was achieved using fibroblast to assess the effects of com-
pounds on cell energy metabolism [84]. This work was 
followed by intensive research to establish an in vitro sys-
tem combining liver cells and metabolomics for the iden-
tification of liver toxicity and modes of action. It has been 
observed that identification of liver toxicity can indeed 
be achieved by in  vitro metabolomics using the HepG2 
liver cell line. Research using cells from other organs is 
continuing; striving for the identification of organ-spe-
cific toxicity. The final goal would be to have a full array 
of cell systems to reliably predict systemic toxicity [85]. 
It is essential that work to obtain such alternative meth-
ods be continued because their availability is needed 
to reduce animal use, reduce the use and production 
of waste, and to increase the utility of such methods in 
chemical screening regulation. With this available, only 
a few grams of compound would be needed to evaluate 
systemic toxicity, and to move ahead one step further in 
the development of Green Chemistry with Green Toxico-
logical methods.
Finally, with the availability of sufficient data on, for 
example, compound–receptor interactions, it is possible 
to create mathematical models which can assign a like-
lihood that a particular chemical structure will interact 
with a biological target. The process of developing such 
models is not necessarily fast and depends very much 
on the quality of the input data. However, the availabil-
ity of such models will help chemists to design new com-
pounds that perform the desired task and have a higher 
likelihood of a favourable toxicological profile. Safety-by-
design will result in a win–win situation, with less animal 
testing and intrinsically safer products.
Green Toxicology in drug development for human 
safety assessment
In contrast to household and consumer chemicals, 
where the optimization process of the properties during 
product development is often independent of the safety 
assessment, the drug development process can be seen as 
a series of iterative steps to optimize efficacy and simul-
taneously lower the safety as early as possible. Therefore, 
the early assessment of toxicity before the first applica-
tion to man (clinical phase 1) plays a pivotal role in this 
process. Compounds for which the preclinical toxico-
logical assessment identifies an adverse effect profile 
that exceeds the expected benefit for the patient will be 
excluded from progression in the development pipeline. 
Preclinical toxicology is hereby facing two challenges: on 
the one hand, the predictivity of the applied toxicological 
assays should be improved on a continuous basis to avoid 
false predictions (both false positives and false negatives), 
while on the other hand, the predictions should be made 
as early as possible during the process of drug candi-
date selection. This early assessment causes a shift from 
in vivo to in vitro to in silico methods. Maertens et al. [1] 
stress the parallels between the Green Toxicology move-
ment and the strive for early and reliable safety assess-
ment (“front-loading”) in the pharmaceutical industry, 
such that the achievements in meeting the abovemen-
tioned challenges will contribute to the objectives of 
Green Toxicology.
Some toxicological effects can in the meantime be 
predicted based on in silico methods with reasonable 
reliability, such as mutagenicity, phospholipidosis, and 
to a lesser extent skin sensitization [86]. It can be fore-
seen that integrated testing strategies will evolve with 
the advent of AOPs and a better understanding of the 
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mechanisms of toxicological effects, which comprise 
a combination of in silico and in  vitro tools to predict 
toxicological effects. For example, models that predict 
pharmacokinetic behaviour (absorption, distribution) of 
compounds based on physicochemical properties could 
be combined with predictions of liver transport based on 
QSAR transporter models. The inclusion of subsequent 
results from in  vitro toxicity assays with hepatocytes or 
mitochondria will help to identify compounds that have 
a propensity towards drug-induced liver toxicity (DILI). 
Such complementary tools may limit and remove the 
most problematic candidates in early phases or allow 
medicinal chemistry departments to optimize the struc-
ture early on.
Green Toxicology for the early assessment 
of environmental safety
Triggered by numerous publications on occurrence 
of pharmaceuticals in the environment, the European 
Commission was asked to deliver a strategic approach 
to pollution of water by pharmaceutical substances. 
The corresponding report was published in 2013 [87]. 
Regarding green medicinal products, the report con-
cludes that “an approach to minimising the persistence, 
bioaccumulation and impacts of medicinal products on 
the environment would be to promote the replacement of 
substances of concerns by molecules with a more envi-
ronmentally friendly profile or substances which demon-
strated a higher rate of removal in wastewater treatment 
plants and to develop new compounds that are alto-
gether effective, efficient and readily biodegradable in the 
environment.”
Despite these straightforward claims, the advances in 
the field of Green Toxicology for environmental safety 
are less evident than for human safety. The reason for 
this deficit is an inherent conflict of objectives during the 
optimization phase of a drug candidate, which is often 
overlooked in the discussion. One key criterion for low 
human toxicity is the partial stability of a drug candidate 
both with regard to human metabolism, as well as chemi-
cal stability towards light and temperature. Unless we 
consider a so-called pro-drug, which requires metabolic 
activation for achieving efficacy, an otherwise unstable 
compound usually undergoes attrition during the drug 
development. Degradation or rapid metabolism of a drug 
candidate usually results in a lower exposure to the effi-
cacious compound leading to a lower efficacy of disease 
treatment. This lower efficacy could only be overcome 
by increasing the dose, which in turn could result in an 
increased risk of side effects. In addition, particular phase 
I metabolites or breakdown products may elicit adverse 
effects on their own, which can lower the therapeutic 
window.
Striving for optimization of drug stability may result in 
the persistence of the drug after excretion and in sewage 
treatment in the aquatic environment. For some drugs, 
the concentrations reported in certain aquatic environ-
ments raise the concern of causing harm to environmen-
tal species. As a matter of fact, the vast majority of active 
pharmaceutical ingredients show no ready biodegrada-
bility when subjected to the pertinent OECD screening 
tests for ready biodegradability [88]. Furthermore, there 
are currently no reliable tools or assays for predicting 
biodegradability in the early phases of drug development, 
which hinders the appropriate and desirable selection of 
biodegradable compounds. Two case examples are pre-
sented below to illustrate the described difficulties in the 
inclusion of Green Toxicology for environmental safety 
assessment.
Case example 1: the search for biodegradable iodinated X‑ray 
contrast media
Iodinated X-ray contrast media are used to enhance the 
contrast between organs or vessels and surrounding tis-
sues during radiography. After renal excretion, iodinated 
X-ray contrast media contribute to the burden of adsorb-
able organic halogens (AOX) in sewage water [89]. The 
high doses required to achieve radiocontrast can only 
be administered intravenously if the compounds are 
both stable and of extremely low toxicity. It comes as 
no surprise that optimized stability results in a low bio-
degradability (<10% in the test for ready biodegradabil-
ity according to OECD 301) and that the compounds are 
detectable at microgram levels in sewage effluents and 
certain surface waters [89, 90].
In an effort to find alternative chemical core structures 
capable of carrying the radio-dense iodine, while at the 
same time being better biodegradable in the aquatic envi-
ronment, iodine sugars were investigated as candidates 
for X-ray contrast media (Fig. 2). A single iodine bound 
to a monomeric sugar molecule (iodo-glucose) fulfilled 
the criterion of being readily biodegradable (>70% degra-
dation within 21 days). However, the attachment of only 
one iodine atom per sugar molecule was not sufficient 
to achieve the required radiocontrast at a feasible dose. 
Therefore, alternative sugar dimers carrying two iodine 
atoms were investigated, but these showed a significant 
decrease in the degradability. In addition, the toxicity 
of the iodine sugar dimer proved to be 8.3 times greater 
compared with the conventional contrast media in 
rodent studies. Furthermore, the sugar dimer showed low 
heat stability (i.e. it was not amenable to heat steriliza-
tion), which is a prerequisite for an injectable compound, 
if costly filtration sterilization is to be avoided. Due to 
these significant drawbacks, the chances of success in 
the search for alternative structures were considered to 
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be inherently low, and the programme was subsequently 
stopped.
Case example 2: glufosfamide—a model compound 
for benign‑by‑design?
The two oxazaphosphorines, ifosfamide and cyclophos-
phamide, belong to the most frequently used antineo-
plastic agents in cancer therapy. Due to their mutagenic 
and carcinogenic potential, concern was raised that the 
compounds might occur in the environment after excre-
tion and cause harm to aquatic species. Both compounds 
showed only minor biodegradability in laboratory-scale 
sewage treatment plants [91].
In 2000, Kümmerer et  al. [92] published biodegrada-
bility data for the cancer drug candidate glufosfamide. 
Glufosfamide is an alkylating agent closely related to 
ifosfamide, in which the AI of the oxazaphosphorines 
(isophosphoramide mustard) is linked to β-d-glucose by 
an O-glycosidic bond (Fig. 3). The intention of this modi-
fication is primarily to utilize the overexpression of glu-
cose transporters (GLUT) in tumour cells for increased 
cellular uptake of the cytotoxic agents into cancer cells 
[93], thereby augmenting the efficacy of this alkylat-
ing drug candidate. Glufosfamide showed a significantly 
higher biodegradability compared with ifosfamide or 
cyclophosphamide; however, the criterion for ready bio-
degradability according to the OECD 301 guidelines was 
also not achieved. A paper by Kümmerer [94] later pos-
tulated that this chemical modification could be taken as 
an example for the “benign-by-design” paradigm since 
this molecule should not only benefit the patient but also 
show advantageous environmental properties.
Unfortunately, and despite encouraging preclinical 
results pointing towards lower toxicity of glufosfamide 
Fig. 2 Degradation of iodinated sugar molecules. a Iodinated glucose is less readily degraded than its parent compound glucose or the reference 
compound sodium acetate (NaAc), but still reaches ready biodegradability within the 21‑d window (dashed line). b The sugar dimer ZK 203014 
with two iodines attached to achieve a higher radiocontrast shows only marginal biodegradability. In both graphs, the “Toxicity Control” depicts 
the result of the degradation of a 1:1 mixture of NaAc plus the test compound (ZK 35299 or ZK 203014). In both cases, these curves approximate 
the combination of the individual degradation curves of NaAc and the test compound, indicating that the test compound does not inhibit the 
degradation of NaAc by microcidal action
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compared with ifosfamide, several clinical trials have not 
resulted in the approval of the potential drug. However, 
orphan drug status was granted for glufosfamide for pan-
creatic cancer by both the U.S. Food and Drug Admin-
istration (2006) and the European Medicines Agency 
(2011) [95]. Clinical Trials [96] list nine studies with glu-
fosfamide between April 2000 and Sept 2013 for a broad 
variety of cancers. Six of these studies are reported as 
“completed”, two as “terminated”, and one is still recruit-
ing in the indication pancreatic cancer.
A review by Calvaresia and Hergenrother [97] discusses 
the high dose-limiting human toxicity towards erythro-
cytes compared with the approved drug ifosfamide, with 
the main cause for the lack of clinical success of this com-
pound stated as: “… the anemia observed may stem from 
the fact that erythrocytes express high levels of GLUT. 
Clinical testing of future glucose conjugated drugs should 
be cognizant of this potential hemolytic phenotype”. Evi-
dently, the glucose modification of the cytotoxic agents 
increase human toxicity rather than increase the efficacy 
of the drug, which contrasts with published preclinical 
results [97]. Thus, it is doubtful whether sugar attach-
ment can be considered as a general design feature for 
degradable drugs due to the toxicity liabilities that such a 
chemical modification might introduce.
Concluding the two presented case studies, there are 
currently no straightforward strategies available for the 
inclusion of Green Ecotoxicology into the early phases of 
drug development.
Green Toxicology for nanomaterials: read‑across 
and grouping as tools for predictivity
Over the last two decades, nanomaterials are more and 
more in the focus of scientists, production companies, 
but also of regulators. This family of relatively new com-
pounds and materials is different from the normal defi-
nition of chemical compounds. Chemical substances are 
usually described by their chemical composition but in 
the case of nanomaterials, additional descriptors such as 
particle size, shape or composition of core and coatings 
are needed to specify and distinguish them from each 
other. As a consequence, a virtually unlimited num-
ber of different nanomaterials can be identified, which 
may result in a burdensome request for a large amount 
of toxicological data for regulatory hazard assessment. 
It is important to ensure that the development of new 
nanotechnology occur in the presence of Green Toxicol-
ogy and Chemistry practices (e.g. focus on preventive 
design). A framework for chemists and material develop-
ers is needed to clearly outline design rules that integrate 
health, safety, and environmental concerns into nano-
technology development [98]. Thus, for Nanotechnology 
as a relatively young technology, the opportunity exists to 
start early on with the implementation of the principles 
of Green Toxicology. However, as highlighted by Hansen 
et  al. [98] research on the sustainability of materials 
must be funded at levels significant enough to identify 
early warnings, and regulatory systems should provide 
incentives for safer sustainable materials. Two examples 
of common nanotechnology are presented below that 
emphasize the complexity of early warning identification 
and integration of Green Toxicology practices.
Case 1: metal oxides such as titanium dioxide as inert 
substitutes
Cosmetics, especially sunscreens, should protect us from 
ultraviolet (UV)-light induced sunburn and skin can-
cer. This protection has been achieved by a multitude of 
chemicals with different structures, some of which are 
under suspicion of being endocrine disruptors or of hav-
ing other effects in environmental organism in receiv-
ing aquatic environments. Over the last two decades, 
nanoparticles consisting of ZnO or  TiO2 have been used 
as very efficient physical UV-blocking materials. As the 
natural background for  TiO2 is relatively high in surface 
water, such as lakes and rivers [99], the use of  TiO2 as a 
UV-blocking agent is less hazardous than the “normal” 
chemical cocktail in sun creams. However, recently an 
intense discussion was started on the possible carcino-
genic effect in the lung after inhalation of sun screens, 
Fig. 3 Structures of the marketed alkylating agent ifosfamide (a) and its glucose derivative, glufosfamide (b)
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as the International Agency for Research on Cancer 
(IARC) stated: “Titanium dioxide is [a] possible carci-
nogenic to humans (Group 2B) based on sufficient evi-
dence in experimental animals and inadequate evidence 
from epidemiological studies” [100]. This example brings 
together considerations about a product that has been on 
the market for decades, despite outcomes of experiments 
describing relatively severe effects in cells or animals. The 
idea of Green Toxicology may help to resolve this prob-
lem by introducing specific information about the mate-
rials used and by establishing relationships between the 
properties of the  TiO2-particles and the predicted out-
comes. Comparisons of the materials used for the criti-
cal animal studies with that produced for the sunscreens 
should allow for the determination of the similarities 
in the materials and if the benign-by-design principle 
should be considered more thoroughly for future devel-
opment of sunscreens.
Case 2: carbon nanotubes—possible carcinogens 
but degradable?
Another critical nanomaterial is carbon nanotubes 
(CNTs), a lightweight but very strong material with a 
multitude of different possible applications in its various 
modifications (i.e. single-walled and multi-walled CNTs 
with different conformations). This material is described 
to have a strong similarity to asbestos with respect to the 
adverse health effects caused via inhalation. The proper-
ties of CNTs, such as the biopersistent, long fibre-like 
structure, and induction of oxidative stress, lead to the 
same biological consequences in lung tissue as asbestos, 
and thus, the use of CNTs is still under debate regarding 
the carcinogenic effect. However, following the important 
principle “benign-by-design”, recent studies have dem-
onstrated that CNTs are biodegradable under specific 
circumstances, which would dramatically reduce their car-
cinogenic potency [101, 102]. In addition, it has recently 
been demonstrated that short fibre lengths less than 5 µm 
are not severely toxic and that only long and rigid CNTs 
have an asbestos-like effects [103]. Hence, this case study 
is an example of a situation where toxicological informa-
tion for the production of benign CNTs already exists and 
should be used for future development of products.
Nanomaterials—endless variability needs new tools 
for assessment
As mentioned above, more and more products that con-
sist of or contain nanomaterials will soon enter the mar-
ket or are already in use. An adequate risk assessment 
of environment and health is seemingly not possible 
because of the tremendous need for biological experi-
ments, animal testing and laboratory capacity. The use-
fulness and applicability of in  vitro methods must be 
demonstrated on a case-by-case basis, but they represent 
enabling technologies to address these demands [104, 
105]. There are also opportunities for in silico approaches 
and pragmatic solutions such as grouping and thresh-
olds of toxicological concern. Thus, the concepts of read-
across and grouping, which are described in detail for 
chemicals by the OECD and ECHA, should also be intro-
duced for nanomaterials. In short, read-across is defined 
by ECHA as “the use of relevant information from anal-
ogous substances (the ‘source’ information) to predict 
properties of the ‘target’ substance(s) under considera-
tion” [106]. As mentioned earlier, the starting position for 
this approach is the formation of groups of chemicals or 
materials which have the same properties for a specific 
aspect. The OECD defines this approach as follows, “the 
term ‘grouping’ or ‘chemical grouping’ describes the gen-
eral approach for considering more than one chemical 
at the same time” [107]. Thus, a grouping of nanomate-
rials combined with a corresponding evaluation and test 
strategy based on, for example, their physicochemical 
properties or toxicological characteristics, would reduce 
regulatory testing efforts. This has already been recog-
nized early on and several grouping frameworks have 
been proposed [108–113]. The concept of Walser et  al. 
[111] proposes as the first step to group the unlimited 
nanomaterials identified into a limited number of enti-
ties. The chemical composition of each structural ele-
ment (core, coating, etc.), size distribution, and shape 
are subdivided into predefined toxicologically relevant 
bands, wherein read-across criteria can be applied. These 
biunique entities may include many similar nanomaterial 
identities, which are considered the same from a regula-
tory perspective. In a second step, entities are allocated to 
groups (clouds), which represents specific testing strate-
gies for toxicological endpoints that need further evalu-
ation [111]. This allocation is driven by AOPs [27], in 
which key events are triggered in a cascade-like manner, 
ultimately leading to an undesirable biological response 
[114, 115].
In addition to hazard-oriented key events, properties 
such as stability or bioaccumulation can serve as further 
building blocks for testing strategies [116]. Bio-persistent 
accumulative entities of nanomaterials, capable of induc-
ing key events responsible for long-term toxicity, would 
be allocated to a testing strategy where further testing is 
needed. In contrast, nanomaterials that are not trigger-
ing such key events would be allocated to a group where 
no such additional testing is required. The assignment of 
substances and nanomaterials to predefined testing strat-
egies based on AOPs further support Green Toxicology. 
Data on the induction of key events of relevant AOPs 
could be screened by in  vitro assays and serve as gate-
keepers in innovation processes.
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Conclusions
The cases shown above for chemical and pharmaceuti-
cal companies, as well as nanotechnology development, 
clearly demonstrate that Green Chemistry, together 
with the principles of Green Toxicology more specifi-
cally related to the environmental and health effects 
of compounds or materials, may achieve a sustainable 
and safe production scenario of new chemicals. How-
ever, in the case of pharmaceutical compounds, there 
may also be limitations with regard to achieving safe 
and efficacious drugs that are at the same time environ-
mentally friendly. As the examples from the European 
Environmental Agency (EEA) demonstrate [16], it is 
now the duty of all the stakeholders to implement such 
rules for a responsible production of new compounds 
and materials based on common principles. Taking the 
ideas of Maertens et al. [1] as a basis, the principles of 
Green Toxicology may be further expanded. It is not 
only important to test early, but to also try to achieve 
safety-by-design of the compounds, to use predictive 
test systems, and to avoid exposure. Overall, testing 
itself must be sustainable and safe by avoiding solvents 
that may be hazardous or energy consuming, and test-
ing should help to reduce the need of experimental 
animals. Moreover, the ideas and fundamental rules of 
toxicology should be familiar for all chemists but also 
to physicists and engineers. Thus, a transdisciplinary 
education in toxicology would be helpful to implement 
this knowledge in the processes for chemical develop-
ment (Fig. 1).
Last but not least, such measures are not free of charge, 
hence, all stakeholders should be convinced to use these 
principles and the consumer has to accept the higher 
costs for such products. As a very important step in pro-
ducing chemicals and materials for future applications 
regarding environmental- and health-safety issues, the 
goals of Green Toxicology have to be accepted by all soci-
etal groups.
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